ImmunityBio, Inc. Common Stock
IBRX
$8.48
+0.24%
ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate both the adaptive and innate immune systems to fight cancer and infectious diseases. Its lead asset, ANKTIVA (nogapendekin alfa inbakicept), is an IL-15 superagonist that has received FDA approval for non-muscle invasive bladder cancer and is being expanded into additional indications and geographies. The company is distinct as a vertically integrated immunotherapy platform player, with a portfolio spanning adenovirus-vectored vaccines, NK-cell therapies, and immunomodulators, and it operates primarily in the United States with growing European and Asian commercialization efforts. The current investor narrative centers on ANKTIVA's regulatory momentum—including FDA acceptance of an expanded-use filing, EU approval, and a first approval in Asia—alongside a new exclusive Japanese BCG partnership and an NCCN guideline endorsement, which collectively support a potential inflection in revenue. However, the stock remains highly speculative, with a 75% decline since IPO, persistent losses, and a very high short interest ratio of 14.71, reflecting deep debate over execution and financing risk.…
IBRX
ImmunityBio, Inc. Common Stock
$8.48
Related headlines
Investment Opinion: Should I buy IBRX Today?
Based on the synthesis of data, IBRX warrants a speculative Buy rating for risk-tolerant investors. The core thesis is that ANKTIVA's regulatory momentum and early revenue traction, combined with a strong analyst consensus (average target $12.75, implying 50.4% upside), offer an attractive risk/reward for those who can stomach extreme volatility. However, the company's negative cash flow and premium valuation necessitate a high-risk tolerance.
Supporting evidence includes: 1) Revenue growth trajectory with Q4 2025 revenue of $38.29 million, up 4.07% YoY and sequentially higher for four quarters; 2) Exceptional gross margin of 88.91% (99.34% TTM), indicating strong pricing power; 3) Analyst consensus of Strong Buy with a tight target range of $12-$15, suggesting high conviction; 4) Improving net loss from $129.65 million in Q1 2025 to $61.94 million in Q4 2025, showing operating leverage. However, the PS ratio of 16.08x is at a premium to the industry, and free cash flow is deeply negative at -$308.01 million TTM.
The biggest risks are financing risk (negative equity, high cash burn), execution risk (revenue growth must accelerate), and valuation risk (EV/Sales of 59.34x). The rating would upgrade to a strong Buy if revenue growth accelerates above 20% YoY and cash burn moderates, or downgrade to Hold if growth stalls or a dilutive financing occurs below $7.00. Relative to its history, the stock is not cheap, but the premium may be justified by the large addressable market and regulatory catalysts. Overall, it is a high-risk, high-reward speculative buy.
Sign up to view all
IBRX 12-Month Price Forecast
IBRX presents a high-risk, high-reward opportunity driven by ANKTIVA's regulatory progress and early commercial traction. The stock's 197.5% one-year gain reflects optimism, but valuation multiples are stretched, and cash burn remains a critical concern. Analyst sentiment is strongly positive, yet the high short interest signals deep skepticism. I would upgrade to bullish if revenue growth accelerates above 20% YoY and the company secures non-dilutive financing; I would downgrade to bearish if growth stalls or a dilutive financing occurs below $7.00. The risk/reward is balanced, favoring a neutral stance with a speculative tilt.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on ImmunityBio, Inc. Common Stock's 12-month outlook, with a consensus price target around $12.75 and implied upside of +50.4% versus the current price.
Average Target
$12.75
0 analysts
Implied Upside
+50.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$12 - $15
Analyst target range
Four analysts cover IBRX, with a consensus recommendation of "strong_buy" (recommendation mean of 1.25) and an average target price of $12.75. This implies an upside of approximately +50.4% from the current price of $8.48. The consensus is decidedly bullish, with all recent ratings being Buy or Overweight from firms including D. Boral Capital, Piper Sandler, and HC Wainwright & Co., and no sell ratings. The bullish stance is underpinned by the recent regulatory wins and the potential for ANKTIVA to capture significant market share in bladder cancer. The target price range is relatively tight, from a low of $12.00 to a high of $15.00, suggesting strong conviction among analysts. The low target of $12.00 still implies +41.5% upside and likely assumes successful execution of the current launch and expansion into Europe and Asia, but with conservative penetration rates. The high target of $15.00 (+76.9% upside) likely prices in rapid adoption, additional indication approvals, and possibly partnership revenues. The narrow spread indicates that analysts share a similar view on the company's prospects, reducing uncertainty compared to typical early-stage biotechs. Institutional ratings show a pattern of reiterations rather than upgrades or downgrades, with D. Boral Capital repeatedly maintaining Buy ratings throughout 2026, and Piper Sandler and HC Wainwright also reaffirming positive views. This consistency suggests that analysts are waiting for further clinical or commercial data to adjust their models, but the overall sentiment remains strongly positive.
Bulls vs Bears: IBRX Investment Factors
The bull case for IBRX rests on tangible regulatory progress, a clear revenue inflection, and strong analyst support, while the bear case centers on extreme valuation, cash burn, and financing risk. Currently, the bull evidence appears stronger due to recent FDA acceptance, EU approval, and Asian market entry, which collectively de-risk the commercial trajectory. However, the single most important tension is whether ANKTIVA's revenue ramp can accelerate enough to justify the 16x PS multiple before the company exhausts its cash reserves. If revenue growth stalls or financing becomes dilutive, the bear case could quickly dominate. Conversely, continued regulatory wins and partnership revenues could drive the stock toward analyst targets.
Bullish
- Regulatory Momentum Accelerating: The FDA accepted an expanded-use filing for ANKTIVA in May 2026, following EU approval in February 2026 and a first Asian approval in March 2026. These milestones validate the clinical profile and open multiple new markets, with the NCCN guideline endorsement further boosting adoption.
- Revenue Inflection Underway: Q4 2025 revenue reached $38.29 million, up 4.07% year-over-year and marking the fourth consecutive quarter of sequential growth from $16.52 million in Q1 2025. This trajectory suggests the commercial launch is gaining traction.
- Exceptional Gross Margins: Gross margin stands at 88.91% for Q4 2025 and 99.34% on a trailing twelve-month basis, reflecting the high-value nature of ANKTIVA. This provides significant operating leverage as revenue scales.
- Strong Analyst Consensus: All four covering analysts rate IBRX a Buy or Overweight, with a consensus recommendation mean of 1.25 (Strong Buy) and an average target price of $12.75, implying 50.4% upside from the current $8.48.
Bearish
- Severe Cash Burn and Negative Equity: Free cash flow TTM is -$308.01 million, and operating cash flow in Q4 was -$70.38 million. The debt-to-equity ratio is -1.76 due to negative shareholder equity, highlighting reliance on external financing and dilution risk.
- Extreme Valuation Multiples: The price-to-sales ratio is 16.08x and EV/Sales is 59.34x, far above the 5-15x range typical for commercial-stage biotechs. This prices in near-perfect execution and rapid multi-indication uptake.
- High Short Interest Signals Skepticism: Short ratio of 14.71 indicates significant bearish positioning, reflecting doubts about the company's ability to fund operations without substantial dilution or partnership revenues.
- Modest Revenue Growth Relative to Valuation: Year-over-year revenue growth of 4.07% in Q4 2025 is modest compared to the massive market opportunity and the valuation multiple. Sustaining acceleration is critical to justify the premium.
IBRX Technical Analysis
IBRX is in a powerful long-term uptrend, with a 1-year price change of +197.54% and a year-to-date gain of +319.80%, massively outperforming the S&P 500's +15.01% and +11.70% over the same periods. The current price of $8.48 sits at approximately 62% of the 52-week range (low of $1.95, high of $12.43), indicating the stock is in the upper half of its annual range but not at its highs, suggesting room for continued momentum if catalysts materialize. This positioning reflects a recovery from deep lows rather than an overextended breakout, though the magnitude of the move warrants caution about profit-taking. Recent momentum is positive but decelerating: the 1-month change is +4.31% and the 3-month change is +15.22%, both well below the 1-year gain, while the 6-month change is just +0.12%, revealing a period of consolidation. The 1-month relative strength versus SPY is +5.27%, and the 3-month relative strength is +13.22%, confirming outperformance, but the 6-month relative strength is -17.32%, highlighting a mid-year pullback. This divergence suggests the stock is in a re-accumulation phase after a sharp run, with the 1-month trend potentially signaling a resumption of the longer-term uptrend if volume confirms. Key technical support lies near the 52-week low of $1.95, though a more immediate support zone is around the $7.00–$7.50 area, which has been tested multiple times in recent months. Resistance is defined by the 52-week high of $12.43; a breakout above this level on strong volume would signal a new leg higher and likely attract momentum buyers. Conversely, a breakdown below $7.00 would undermine the bullish structure and could trigger a retest of lower levels. The stock's beta of 0.135 is unusually low, implying very low volatility relative to the market, but this is likely a statistical artifact of the stock's idiosyncratic, news-driven nature rather than a true reflection of risk; in practice, IBRX exhibits extreme volatility, as evidenced by a max drawdown of -42.34% and a short ratio of 14.71, which can amplify moves.
Beta
0.14
0.14x market volatility
Max Drawdown
-42.3%
Largest decline past year
52-Week Range
$2-$12
Price range past year
Annual Return
+197.5%
Cumulative gain past year
| Period | IBRX Return | S&P 500 |
|---|---|---|
| 1m | +4.3% | -0.5% |
| 3m | +15.2% | +2.3% |
| 6m | +0.1% | +16.6% |
| 1y | +197.5% | +14.8% |
| ytd | +319.8% | +11.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IBRX Fundamental Analysis
IBRX's revenue trajectory is inflecting upward, with Q4 2025 revenue of $38.29 million representing 4.07% year-over-year growth, a sharp acceleration from the $7.55 million in Q4 2024. The multi-quarter trend shows consistent sequential growth: from $16.52 million in Q1 2025 to $26.43 million in Q2, $32.06 million in Q3, and $38.29 million in Q4, driven almost entirely by product revenue ($38.27 million) related to ANKTIVA's launch. This ramp is early-stage but encouraging, implying that the commercial infrastructure build-out is beginning to bear fruit; however, the growth rate remains modest relative to the massive market opportunity, and the company must sustain this trajectory to justify its valuation. Profitability remains deeply negative: Q4 2025 net income was -$61.94 million, with a net margin of -161.8% and an operating margin of -168.95%. Gross margin is exceptionally high at 88.91% (and 99.34% on a TTM basis), typical for a biotech with a proprietary drug, but operating expenses—particularly R&D at $60.81 million and SG&A at $37.83 million in Q4—continue to outpace revenue. The loss narrowed from -$129.65 million in Q1 2025 to -$61.94 million in Q4, indicating improving operating leverage as revenue scales, but the company is still far from breakeven. The balance sheet shows a current ratio of 5.10, indicating strong short-term liquidity, but the debt-to-equity ratio of -1.76 is negative due to negative shareholder equity, a red flag. Free cash flow TTM is -$308.01 million, and operating cash flow in Q4 was -$70.38 million, meaning the company is burning significant cash and relies on external financing—Q4 saw $53.74 million in common stock issued and $54.89 million in net financing. ROE is 70.34% but distorted by negative equity, while ROA is -30.54%, reflecting poor asset efficiency. The company's survival depends on continued access to capital markets or partnership revenues, and the high short ratio suggests skepticism about its ability to fund operations without dilution.
Quarterly Revenue
$38285000.0B
2025-12
Revenue YoY Growth
+406.9%
YoY Comparison
Gross Margin
88.9%
Latest Quarter
Free Cash Flow
$-308007000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IBRX Overvalued?
Since IBRX has negative net income (EPS of -$0.19) and negative EBITDA, the PE ratio is not meaningful; the most appropriate metric is the price-to-sales (PS) ratio, which stands at 16.08x on a trailing basis. The forward PE is -66.95, also negative, and the EV/Sales ratio is 59.34, reflecting the company's debt and cash position. The gap between trailing and forward estimates is not applicable due to negative earnings, but the forward PS, if calculated on estimated revenue of $2.55 billion, would be approximately 0.7x, implying the market expects explosive revenue growth—a massive disconnect that highlights the speculative nature of the valuation. Compared to the biotechnology industry, where price-to-sales ratios for commercial-stage companies often range from 5x to 15x, IBRX's 16.08x is at a premium, but this is somewhat justified by its high gross margin (99.34%) and the large addressable market for ANKTIVA. However, the EV/Sales of 59.34 is exorbitant and suggests the market is pricing in near-certain approval and rapid uptake across multiple indications. The PS ratio has compressed dramatically from historical levels: in Q4 2024, it was 248.54x, and in Q1 2025, it was 155.48x, falling to 51.18x in Q4 2025 and now 16.08x. This compression reflects revenue growth outpacing stock price appreciation, but the current level is still elevated relative to the company's own history when revenue was negligible. The stock is not cheap on any metric, and the valuation hinges entirely on future cash flows that are years away.
PE
-5.2x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-11.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are substantial. IBRX reported a Q4 2025 net loss of $61.94 million and free cash flow TTM of -$308.01 million, indicating a severe cash burn that necessitates frequent capital raises. The debt-to-equity ratio of -1.76 reflects negative shareholder equity, a red flag for financial stability. Additionally, revenue is concentrated in a single product, ANKTIVA, with Q4 2025 product revenue of $38.27 million; any setback in its commercialization or regulatory status would be devastating. The company's survival hinges on continued access to capital markets, and the high short ratio of 14.71 suggests investors are skeptical about its ability to fund operations without significant dilution.
Market and competitive risks are equally concerning. The stock trades at a PS ratio of 16.08x and EV/Sales of 59.34x, well above the 5-15x range for commercial-stage biotechs, leaving it vulnerable to valuation compression if growth disappoints. The beta of 0.135 is misleadingly low due to the stock's idiosyncratic, news-driven nature; in practice, IBRX exhibits extreme volatility, as evidenced by a max drawdown of -42.34%. Competitive threats include other bladder cancer therapies and potential new entrants, while regulatory hurdles in additional indications could delay expansion. Recent news highlights both progress and risk: the FDA acceptance of an expanded-use filing is positive, but the stock remains highly speculative after a 75% decline since IPO.
In a worst-case scenario, a failed clinical trial, regulatory rejection, or financing crunch could trigger a sharp decline. The 52-week low is $1.95, representing a potential 77% loss from the current price of $8.48. Analyst low target is $12.00, but that assumes successful execution; if the bear case materializes, the stock could retest historical lows. A realistic downside scenario might see the stock fall to $3-$4, a loss of 53-65%, if revenue growth stalls and the company is forced to raise capital at unfavorable terms. The high short interest could amplify downward moves, creating a vicious cycle.
FAQ
The most severe risk is financing: IBRX has negative equity (D/E -1.76) and burns ~$70 million per quarter, necessitating dilutive capital raises. Second, commercial execution risk: Q4 2025 revenue growth of 4.07% YoY is modest and must accelerate to justify valuation. Third, regulatory risk: the expanded-use filing could face delays or rejection. Fourth, competitive risk: other bladder cancer therapies may erode ANKTIVA's market share. High short interest (14.71) amplifies volatility. Ranked by severity: financing, execution, regulatory, competitive.
Our 12-month forecast has a base case (50% probability) of $10-$12.75, assuming steady revenue growth and successful financing. The bull case (30%) targets $12-$15 if expanded approvals and partnerships drive rapid adoption. The bear case (20%) sees $3-$6 if growth stalls or financing becomes dilutive. The most likely scenario is the base case, hinging on revenue acceleration to 15-20% YoY and maintaining gross margins above 85%. Analyst consensus average target is $12.75, aligning with our base case.
IBRX appears overvalued on traditional metrics, with a PS ratio of 16.08x and EV/Sales of 59.34x, well above the 5-15x range for commercial-stage biotechs. However, these multiples may be justified if ANKTIVA's revenue grows exponentially; the forward PS on estimated 2026 revenue of $2.55 billion would be ~0.7x, implying the market expects explosive growth. The stock is pricing in near-perfect execution, leaving little room for error. Relative to its own history, the PS has compressed from 248x in Q4 2024, but it remains elevated.
IBRX is a high-risk, high-reward speculative buy for investors with a high tolerance for volatility. The stock has 50.4% upside to the analyst average target of $12.75, supported by regulatory wins and revenue growth. However, the company burns significant cash (-$308 million TTM) and trades at a premium PS of 16.08x. It is suitable only for those who can withstand potential 50%+ drawdowns and have a long-term horizon. Consider position sizing carefully and monitoring quarterly execution.
IBRX is better suited for long-term, risk-tolerant investors who can hold through volatility, given its early commercial stage and binary regulatory catalysts. The stock's beta of 0.135 is misleading; actual volatility is extreme (max drawdown -42.34%), making it unsuitable for short-term trading unless one actively manages positions. A minimum holding period of 2-3 years is recommended to allow ANKTIVA's revenue ramp to materialize and for potential profitability. Short-term traders may exploit news-driven spikes, but the high short interest and low liquidity increase risk.